[Identification of B (A) Blood Group and Blood Transfusion for patients with B (A) Blood Group].

OBJECTIVE: To investigate the serological and molecular biological identification of B(A) blood group and its reasonable method of blood transfusion for patient with B(A) blood group. METHODS: The blood group of patient was detected by serological method, at the some time, the genotype of patient was detected by using the ABO-TYPE Variant kit and sequence analysis of 6 and 7 exons in ABO gene; the washed O red blood cells were used to cross matching blood of difficultly matching blood by the three step analysis method. RESULTS: The A weak and B strong agglutination were found in positive type, and A1C(3+), BC(-) were observed in negative type; the molecular biological identification showed B(A)04, 640 A > G; the matching blood main side of washed O red blood cells displayed no agglutination. CONCLUSION: The identification and analysis of rare blood or subtype should be very careful; if necessary, the molecular biological detection should carried out; the blood transfusion for patient with rate blood group or subtype should be safe, correct and reasonable.

Blockage of tropomyosin receptor kinase a (TrkA) enhances chemo-sensitivity in breast cancer cells and inhibits metastasis in vivo.

Hyper-activation of the Neurotrophin Receptor Signaling contributes to the development and metastasis of breast cancer. The inhibition of growth factor-dependent growth of breast cancer cell demonstrated a promising way for cancer therapy. In this study, the signaling pathway of tropomyosin receptor kinase A (TrkA) had been investigated for the role it played in the proliferation of chemo-resistance of breast cancer cells. Small interference RNA (siRNA) was used to down-regulate the expression of TrkA in breast cancer cell and tumor xenograft mice model. Our results indicated that siRNA mediated down-regulation of TrkA lead to the proliferation inhibition of cancer cells and arrested cells cycle at G0/G1 phase via inactivation of NF-κBp65. Application of TrkA siRNA to cancer cell also increased the chemo-sensitivity to paclitaxel, and further promoted apoptosis in cancer cell through the activation of caspase-3. Moreover, TrkA siRNA increased the efficacy of paclitaxel and decreased the incidence of lung metastasis in tumor xenografted mice. In sum, these results indicate that TrkA signaling plays an important role in breast cancer chemo-resistance and metastasis. It could be a potential pharmacologic target to enhance the effectiveness of chemo-therapy for breast cancer.